New pill targets rare bile duct cancer gene in japanese patients
NCT ID NCT06081829
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests a daily oral drug called ivosidenib in 12 Japanese adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has already been treated with chemotherapy. The goal is to see if the drug can stop or slow the cancer from growing. Participants take the pill in 28-day cycles until the cancer worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital (JPN-006)
Sapporo, 060-8648, Japan
-
Kanagawa Cancer Center (JPN-003)
Yokohama, 241-8515, Japan
-
Kumamoto University Hospital (JPN-004)
Kumamoto, 860-8556, Japan
-
National Cancer Center Hospital (JPN-001)
Tokyo, Japan
-
National Cancer Center Hospital East (JPN-002)
Kashiwa, 277-8577, Japan
-
National Hospital Organization Shikoku Cancer Center (JPN-007)
Matsuyama, 791-0280, Japan
-
Osaka International Cancer Institute (JPN-005)
Osaka, 541-8567, Japan
Conditions
Explore the condition pages connected to this study.